Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 747 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Breast Cancer Survivor Shares Inspiring Images Of Herself As “Bold Indian... March 1, 2019 Single Dose of HPV Vaccine Yields Long-Term Protection from Many Cancer-Causing... April 10, 2020 Mom Gives Birth and Receives a Breast Cancer Diagnosis on the... September 23, 2020 Adjuvant mRNA-4157 Plus Pembrolizumab Prolongs RFS versus Pembrolizumab Alone in Patients... January 23, 2024 Load more HOT NEWS Research with Integrity – the madness of short methods Nomination Process for the 2026 ESMO Society Awards Now Open Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated... How Therapy Helped Me Cope During Cancer: A Survivor’s Perspective
